---
title: "Daily Hong Kong Stock Market News Briefing (November 28, Thursday)"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/220875075.md"
description: "REGINA MIRACLE's interim performance revenue was HKD 3.978 billion, a year-on-year increase of 12.2%, with a net profit of HKD 67.619 million, a year-on-year decrease of 36.7%. Jingji Financial International's interim performance showed a profit attributable to owners of HKD 6.806 million, a year-on-year decrease of 91.12%. Chengdu Gaosu signed a land acquisition and demolition agreement with the Wenjiang District Government. SINO BIOPHARM's Bemarituzumab injection has been approved for market launch. CMS's innovative drug has received clinical trial approval. Shengyang Group completed the issuance of convertible securities amounting to HKD 101 million. Laikang Pharmaceutical-B completed the placement of 17.636 million shares, raising approximately HKD 230 million. JIUYUAN GENE's share price was set at HKD 12.42, with the public offering receiving 675.83 times subscription"
datetime: "2024-11-28T01:10:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/220875075.md)
  - [en](https://longbridge.com/en/news/220875075.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/220875075.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/220875075.md) | [繁體中文](https://longbridge.com/zh-HK/news/220875075.md)


# Daily Hong Kong Stock Market News Briefing (November 28, Thursday)

Individual Stock News

1.  REGINA MIRACLE (02199.HK): The interim performance revenue is approximately HKD 3.978 billion, a year-on-year increase of 12.2%, with a net profit of HKD 67.619 million, a year-on-year decrease of 36.7%.
    
2.  Kingkey Financial International (01468.HK): Announced interim results with a profit attributable to owners of HKD 6.806 million, a year-on-year decrease of 91.12%.
    
3.  Chengdu Expressway (01785.HK): Chengwenqiong Expressway Company signed a land acquisition and demolition agreement with the government of Wenjiang District.
    
4.  SINO BIOPHARM (01177.HK): The indication for Bemarituzumab injection combined with Anlotinib hydrochloride capsules for the treatment of endometrial cancer has been approved for market launch.
    
5.  CMS (00867.HK): The innovative drug GLP-1R/GCGR dual agonist CMS-D005 has received a clinical trial approval notice.
    
6.  Shengyang Group (08163.HK): Completed the issuance of convertible securities with a principal amount of HKD 101 million.
    
7.  Laikang Pharmaceutical-B (02105.HK) completed the placement of 17.636 million shares, raising approximately HKD 230 million.
    
8.  Hansoh Pharmaceutical (03692.HK): The fifth indication application for the new lung cancer drug "Amivantamab" has been submitted for market launch.
    
9.  JIUYUAN GENE (02566.HK): The share price is set at HKD 12.42, with the public offering being 675.83 times oversubscribed

### 相关股票

- [REGINA MIRACLE (02199.HK)](https://longbridge.com/zh-CN/quote/02199.HK.md)
- [JIUYUAN GENE (02566.HK)](https://longbridge.com/zh-CN/quote/02566.HK.md)
- [SBP GROUP (01177.HK)](https://longbridge.com/zh-CN/quote/01177.HK.md)
- [CMS (00867.HK)](https://longbridge.com/zh-CN/quote/00867.HK.md)

## 相关资讯与研究

- [Regina Miracle Renews Connected Sales Deal With Float Group](https://longbridge.com/zh-CN/news/281033759.md)
- [Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update](https://longbridge.com/zh-CN/news/280904911.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-CN/news/281380835.md)
- [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-CN/news/281098039.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md)